FHIT expression in gastric adenocarcinoma. Correlation with disease stage and survival

Cancer

Volumn 88, Issue 1, 2000, Pages 24-34

  Capuzzi, David ^a   Santoro, Emanuele ^b,c   Hauck, Walter W ^b   Kovatich, Albert J ^a   Rosato, Francis E ^b   Baffa, Raffaele ^b   Huebner, Kay ^b   McCue, Peter A ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

Author keywords

Disease stage; Fhit expression; Gastric adenocarcinoma; Survival

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; ADENOCARCINOMA; CASE-CONTROL STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROTEINS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033961251     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000101)88:1<24::AID-CNCR5>3.0.CO;2-W     Document Type: Article

References (37)

1. Wingo P, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
2. Whelan SL, Parkin DM, Masuyer E, editors. Trends in cancer incidence and mortality. IARC scientific pub. no. 102. Lyon, France: IARC, 1993.
3. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics. CA Cancer J Clin 1994;44:7-26.
4. Rugge M, Cassaro M, Leandro G, Baffa R, Avellini C, Bufo P. et al. Helicobacter pylori in promotion of gastric carcinogenesis. Dig Dis Sci 1996;41(5):950-5.
5. Kneller RW, You WC, Chang YS, Liu WD, Zhang L, Zhao L. et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst 1992; 84(16):1261-6.
6. You WC, Zhang L, Yang CS, Chang YS, Issaq H, Fox SD, et al. Nitrite, N-Nitroso compounds, and other analytes in physiological fluids in relation to precancerous gastric lesions. Cancer Epidemiol Biomarkers Prev 1996;5:47-52.
7. Baik SC, Youn HS, Chung MH, Lee WK, Cho MI, Ko GH, et al. Increased oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa. Cancer Res 1996;56(6): 1279-82.
8. Gore RM. Gastric cancer clinical and pathologic features. Radiol Clin North Am 1997;35:295-310.
9. Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ. Prognostic factors in gastric cancer. Mod Pathol 1998;11: 870-7.
10. Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg 1997;84:1651-64.
11. Hermanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH, editors. Prognostic factors in cancer. Berlin: Springer, 1995.
12. Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 1998; 83:1094-101.
13. Ramires M, David L, Leitão D, Seixas M, Sansonetty F, Sobrinho-Simoes M. Ki67 labelling index in gastric carcinomas. An immunohistochemical study using double staining for the evaluation of the proliferative activity of diffuse-type carcinomas. J Pathol 1997;182:62-7.
14. Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996;149:1449-57.
15. Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer. Semin Oncol 1996;23(3):307-15.
16. Sano T, Tsujino T, Yoshida K, Nakayama H, Haruma K, Ito H, et al. Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. Cancer Res 1991;51:2926-31.
17. Schneider BG, Pulitzer DR, Brown RD, Prihoda TJ, Bostwick TJ, Bostwick DG, et al. Allelic imbalance in gastric cancer: An affected site on chromosome arm 3p. Genes Chromosom Cancer 1995;13:263-71.
18. Rao PH, Mathew S, Kelsen DP, Chaganti RS. Cytogenetics of gastric and esophageal adenocarcinomas. 3q deletion as a possible primary chromosomal change. Cancer Genet Cytogenet 1995;81:139-43.
19. Rhyu MG, Park WS, Jung YJ, Choi SW, Meltzer SJ. Allelic deletions of DCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology 1994;106: 1584-8.
20. Tamura G, Ogasawara S, Nishizuca S, Sakata K, Maesawa C, Suzuki Y, et al. Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res 1996;56:612-5.
21. Quiemado L, Seruca R, Costa-Perira A, Castedo S. Identification of two distinct regions of deletion at 6q in gastric carcinoma. Genes Chromosom Cancer 1995;14:28-34.
22. Baffa R, Negrini M, Mandes B, Rugge M, Ranzani GN, Hirohashi S, et al. Loss of heterozygosity for chromosome 11 in adenocarcinoma of the stomach. Cancer Res 1996;56:268-72.
23. Motomura K, Nishisho I, Takai SI, Tateishi H, Okazaki M, Yamamoto M, et al. Loss of alleles at loci on chromosome 13 in human primary gastric cancers. Genomics 1988;2:180-4.
24. Kastury K, Baffa R, Druck T, Ohta M, Cotticelli MG, Inoue H, et al. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996;56:978-83.
25. Ohta M, Inoue H, Cotticeili MG, Kastury K, Baffa R, Palazzo J, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84: 587-97.
26. Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki Y, Iwaya T, et al. Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines. Genes Chromosom Cancer 1997;20:98-102.
27. Huebner K, Garrison PN, Barnes LD, Croce CM. The role of the FRA3B/FHIT locus in cancer. In: Jones CA, editor. Annual review of genetics, vol 32. Palo Alto, CA: Hilda Gould, 1998:7-31.
28. Baffa R, Veronese ML, Santoro R, Mandes B, Palazzo JP, Rugge M, et al. Loss of FHIT expression in gastric carcinoma. Cancer Res 1998;58:4708-714.
29. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis, inhibition of tumorigenicity, and suppression of tumor growth by adenovirus vector-mediated FHIT gene overexpression in vitro and in vivo. Cancer Res 1999;59: 3333-9.
30. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, et al. The tumour suppressor gene FHIT is involved in regulation of apoptosis and cell cycle control in lung cancer cells. Proc Natl Acad Sci USA 1999;96:8489-92
31. Hadaczek P, Siprashvili Z, Markiewski M., Domagala W, Druck T, McCue PA, et al. Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res 1998;58:2946-51.
32. Kovatich A, Friedland DM, Druck T, Hadaczek P, Huebner K, Comis RL, et al. Human chromosome 3p alterations in neuroendocrine lung tumors. Cancer 1998;83:1109-17.
33. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997;94: 13771-6.
34. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C. Loss of FHIT expression in lung cancer and pre-invasive bronchial lesions. Cancer Res 1998;58:5032-7.
35. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J. Clinicopathological significance of Fhit protein expression in Stage 1 non-small cell lung carcinoma. Cancer Res 1998;58:5478-83.
36. Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, Kallioniemi O-P, Barkardottir RB, Kovatich A, et al. Reduced Fhit expression in familial and sporadic breast carcinomas. Cancer Res 1999;59:2682-9.
37. Sorio C, Baron A, Orlandini S, Zamboni G, Pederzoli P, Huebner K, et al. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 1999;59:1308-14.